One North End Avenue ☿ Suite 1111 ☿ New York ☿ New York 10282
Telephone: (877) 898-8038 (212) 791-2911 Fax: 212-791-2917

MEDIA CONTACT: Bill Berry, Berry & Co.: 212-253-8881
INVESTOR RELATIONS CONTACT: Sean Collins, CCG – 310-477-9800, ext. 202

DR. JUBO LIU JOINS IMMTECH CHINA AS DEVELOPMENT LIAISON FOR CLINICAL TRIALS

New York, NY, November 29, 2007 - Immtech Pharmaceuticals, Inc. (AMEX:IMM) is pleased to announce that Jubo Liu, Ph.D., has joined Immtech as Development Liaison for Clinical Trials in China. Dr. Liu will coordinate and manage Immtech's clinical development program in China, which currently includes the phase III clinical trial for pneumocystis pneumonia (PCP).

Cecilia Chan, Vice Chairman of Immtech, stated "Immtech received fast-track status from China's State Food and Drug Administration for our application to conduct the PCP Phase III trial. We are advancing into the commercialization phase and intend to significantly increase our growth opportunities in China. With his experience in drug development and in the areas of marketing and regulatory registration in China, Dr. Liu joins our team as we increase our efforts to bring products to market for the treatment of global infectious diseases."

Dr. Liu left Vertex Pharmaceuticals to join Immtech. A specialist in formulation strategies and drug discovery, he also worked as director of marketing and regulatory registration at Beijing Zhenlingxin Health Consulting in Beijing, China, and has coordinated clinical trials for both domestic and imported drugs in China.

"Immtech's unique focus targeting infectious diseases that internationally affect millions of people, gives Immtech substantial competitive advantages;" said Dr. Liu, adding, "I am excited about having the opportunity to contribute to Immtech's successes."

Dr. Liu earned his Ph.D. from the Department of Pharmaceutical Sciences at the University of Toronto and his Bachelor of Pharmacy at Pharmaceutical University of Shenyang in China.

About Immtech Pharmaceuticals, Inc.
Immtech Pharmaceuticals, Inc. is focused on developing and commercializing drugs to treat infectious diseases. Immtech has advanced clinical programs that include new

treatments for Pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (African sleeping sickness), and a well defined, expanding library of compounds targeting Hepatitis C, fungal infections, and bacterial infections. Immtech holds exclusive worldwide licenses to certain patents, patent applications and technology for products derived from a proprietary pharmaceutical platform. For additional information, please go to http://www.immtechpharma.com.

"Safe Harbor" Statement under the Private Securities Reform Act of 1995: Statements in this press release regarding Immtech Pharmaceuticals, Inc.'s business, including the future prospects for PCP, which are not historical facts are "forward-looking statements" that involve risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the headings "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" in Immtech's annual report on Form 10-K for the year ended March 31, 2007 and in its other SEC filings and include: (i) Immtech's ability to develop commercially viable products; (ii) Immtech's ability to achieve profitability; (iii) Immtech's ability to retain key personnel; (iv) the ability of Immtech's scientists and collaborators to discover new compounds; (v) the availability of additional research grants; (vi) Immtech's ability to obtain regulatory approval of its drug candidate, including PCP; (vii) the success of Immtech's clinical trials; (viii) dependence upon and contractual relationship with partners; (ix) Immtech's ability to manufacture or to have a third party manufacture its drug candidate at a reasonable cost; (x) Immtech's ability to protect its intellectual property; (xi) competition and alternative technologies; (xii) Immtech's ability to obtain reimbursement from third party payers for any product it commercializes; and (xiii) potential exposure to significant product liability.

# # #